BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10404342)

  • 21. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.
    Kühn F; Cottagnoud M; Acosta F; Flatz L; Entenza J; Cottagnoud P
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2487-91. PubMed ID: 12878509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
    Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
    Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
    J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
    Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Lister PD; Sanders CC
    J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Cha R; Akins RL; Rybak MJ
    Pharmacotherapy; 2003 Dec; 23(12):1531-7. PubMed ID: 14695032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae.
    Bantar C; Nicola F; Arenoso H; Soutric J; Caruso N; Fernández Canigia L
    J Chemother; 2004 Jun; 16(3):248-54. PubMed ID: 15330320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.
    Davies BI; Maesen FP
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():83-90. PubMed ID: 10404344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
    Hart D; Weinstein MP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):375-8. PubMed ID: 17449210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; González N; Echeverría O; Torrico M; Martín JE; Valdés L; Prieto J
    J Chemother; 2007 Dec; 19(6):670-2. PubMed ID: 18230548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates.
    Miller D; Alfonso EC
    Cornea; 2004 Apr; 23(3):289-93. PubMed ID: 15084863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.
    Cottagnoud P; Cottagnoud M; Acosta F; Flatz L; Kühn F; Stucki A; Entenza J
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):656-62. PubMed ID: 14557920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
    Fuchs PC; Barry AL; Brown SD
    J Chemother; 1997 Dec; 9(6):391-3. PubMed ID: 9491837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits.
    Barry AL; Fuchs PC; Allen SD; Brown SD; Jorgensen JH; Tenover FC
    J Antimicrob Chemother; 1996 Feb; 37(2):365-9. PubMed ID: 8707749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
    Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
    Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.